聚焦艾昆纬-多发性骨髓瘤的微小残留病:加速批准的关键监管里程碑(英)-2026。iqvia.com | 3 Using MRD as a surrogate primary endpoint for accelerated approval Considering the improved survival rates and increased life expectancy for patients with MM, developing treatments to address the remaining unmet needs could require clinical trials that last more than 10 years.
聚焦艾昆纬-多发性骨髓瘤的微小残留病:加速批准的关键监管里程碑(英)-2026。iqvia.com | 3 Using MRD as a surrogate primary endpoint for accelerated approval Considering the improved survival rates and increased life expectancy for patients with MM, developing treatments to address the remaining unmet needs could require clinical trials that last more than 10 years.
聚焦艾昆纬-多发性骨髓瘤的微小残留病:加速批准的关键监管里程碑(英)-2026。iqvia.com | 3 Using MRD as a surrogate primary endpoint for accelerated approval Considering the improved survival rates and increased life expectancy for patients with MM, developing treatments to address the remaining unmet needs could require clinical trials that last more than 10 years.
覆盖 2026 年,全文共 13 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了监管、艾昆纬、多发性骨髓瘤的微小残留病、加速批准的关键监管里程碑等议题。